Proin for Dogs: Phenylpropanolamine for Urinary Incontinence

Last updated: May 25, 2026

What Proin Is and What It Treats

Proin for dogs is the brand name for phenylpropanolamine (PPA), an alpha-adrenergic agonist used to treat urinary incontinence in dogs caused by urethral sphincter mechanism incompetence (USMI). PPA strengthens the muscle tone of the urethral sphincter, helping the bladder hold urine effectively until the dog chooses to urinate. The result for many dogs is dramatic improvement in leaking, often within days of starting therapy.

Urinary incontinence in dogs most commonly affects spayed female dogs, particularly larger breeds, but it can occur in male dogs and intact females as well. The condition often develops months to years after spay surgery as estrogen levels decline and the urethral sphincter muscle loses some of its tone. Other causes exist, including congenital issues and neurologic disease, but USMI is the most common scenario where Proin is prescribed.

For broader background on this distressing condition, our urinary incontinence in dogs guide explains the workup process, including ruling out urinary tract infections and other contributors. Proin is one of the main medical management options once a diagnosis is confirmed and other causes have been excluded.

Current US Regulatory Status

Phenylpropanolamine has an interesting regulatory history. Decades ago it was widely used in human medicine as a decongestant and appetite suppressant, but it was withdrawn from human over-the-counter products due to safety concerns and methamphetamine precursor concerns. In the United States, PPA is now a veterinary prescription medication.

Some states have additional restrictions on PPA dispensing because of its history as a methamphetamine precursor in clandestine drug manufacturing. The current regulatory framework keeps it a veterinary prescription product, and your vet’s clinic dispenses it directly or through a partnered pharmacy. The medication remains widely available for legitimate veterinary use.

Proin specifically (the FDA-approved veterinary brand) is available in chewable tablets and extended-release tablet formulations. The chewable tablets are typically dosed two to three times daily, while the extended-release version provides once-daily dosing for many dogs. Your vet will recommend the formulation based on your dog’s needs and tolerance.

How Phenylpropanolamine Works

PPA stimulates alpha-adrenergic receptors in the urethral sphincter, increasing muscle tone and the resistance to urine outflow. The result is that the bladder can hold urine more effectively without involuntary leaking. The effect is mechanical strength rather than altered sensation or behavior.

The drug is absorbed orally and reaches peak effect within an hour or two of dosing. Duration of effect depends on the formulation: chewable tablets provide a few hours of peak effect with declining activity over the dosing interval, while extended-release tablets provide more sustained activity over 24 hours.

For dogs whose incontinence varies through the day or who only leak overnight, dose timing matters. Your vet can help you align dose timing with the times of day your dog most needs urethral support, particularly if you are using the shorter-acting chewable formulation.

How Proin Is Dosed

Proin chewable tablets are typically dosed at a starting dose calculated by body weight and given two to three times daily. Many vets start at the lower end of the dose range and titrate upward as needed based on response. This conservative approach reduces the chance of side effects while finding the lowest effective dose.

Proin ER (extended release) is dosed once daily and is convenient for owners who would struggle with multiple daily doses. The tablets must be given whole and not crushed or split, because cutting or crushing destroys the extended-release mechanism and can deliver the entire daily dose at once, which can cause significant side effects.

Always follow your veterinarian’s dosing instructions exactly. Changes in dose without veterinary guidance can either fail to control leaking or cause adverse reactions. If a dose seems insufficient, communicate with your vet about a planned adjustment rather than increasing on your own.

Blood Pressure: The Key Monitoring Concern

The most important side effect concern with Proin is elevated blood pressure. PPA’s alpha-adrenergic effects extend beyond the urethral sphincter to the cardiovascular system, where increased vascular tone can raise systemic blood pressure. Dogs with pre-existing hypertension, kidney disease, or cardiac disease are at higher risk.

Your vet should measure baseline blood pressure before starting Proin and recheck it at intervals during therapy, particularly during dose increases or when adding other medications. Hypertension in dogs often has no external signs, so monitoring is the only way to catch problems before they cause damage.

Dogs with cardiac murmurs, kidney disease, or known hypertension may still be candidates for Proin if monitored closely, but the threshold for caution is higher. Your vet may start at a lower dose, monitor blood pressure more frequently, or choose alternative therapies depending on the overall health picture.

Other Side Effects to Watch For

Beyond hypertension, side effects of Proin can include restlessness, agitation, decreased appetite, increased thirst or urination (sometimes paradoxical given the underlying disease), and gastrointestinal upset. These effects are more common at higher doses and often improve with dose reduction or with administration alongside food.

Behavioral changes occasionally occur, with some dogs becoming notably more anxious, restless, or vocal on Proin. These changes typically appear early in therapy or after dose increases. If your dog seems uncomfortable in their behavior on the medication, talk to your vet about adjustments.

Severe reactions including significant hypertension, cardiac arrhythmias, neurological signs, or collapse warrant immediate veterinary attention. While these are uncommon, they are recognized risks and should never be ignored if they develop.

When Proin Should Not Be Used

Proin should generally be avoided in dogs with severe uncontrolled hypertension, significant heart disease (particularly arrhythmias or hypertrophic cardiomyopathy), severe kidney disease, hyperthyroidism, glaucoma, or diabetes mellitus that is poorly controlled. Each of these conditions can be worsened by alpha-adrenergic stimulation.

Pregnant or nursing dogs should not receive Proin because of potential effects on uterine tone and pup safety. Dogs who have had reactions to other sympathomimetic drugs may also be at higher risk for problems with Proin.

Tell your vet about every medication, supplement, and over-the-counter product your dog takes before starting Proin. Drug interactions with antidepressants, certain anesthetic agents, NSAIDs, and other cardiovascular medications can occur, and the medication list informs safe dosing.

Estrogen-Based Alternative Therapies

An alternative to Proin for postspay urinary incontinence in some female dogs is estrogen replacement therapy, typically using estriol (Incurin in some markets) or diethylstilbestrol (DES) compounded as needed. Estrogen restores some of the urethral sphincter tone lost after spay surgery through a different mechanism than PPA.

Estrogen therapy and Proin can sometimes be combined in dogs who do not respond adequately to either alone. The combination produces additive effects through different pathways. As always, this requires veterinary guidance because of the additional drug interactions and monitoring considerations.

For some dogs, the estrogen route is preferred because it avoids cardiovascular concerns. For others, Proin is preferred because of the simpler monitoring and avoidance of estrogen-related effects. The right choice depends on the individual dog’s health profile and response.

Workup Before Starting Proin

Before starting Proin, your vet will typically perform a urinalysis and urine culture to rule out a urinary tract infection, which can mimic or worsen incontinence. Bloodwork including kidney values and ideally blood pressure measurement provides baseline data for monitoring during therapy.

For dogs with atypical signs, additional workup may include abdominal imaging, neurologic assessment, and sometimes specialized tests like contrast studies of the lower urinary tract. The goal is to confirm that USMI is the actual problem rather than a different cause that would not respond to Proin. For dogs whose original spay surgery contributed to later incontinence, our overview of the spaying and neutering guide covers the broader picture of when surgery happens and what owners should know about long-term effects.

If a UTI is found, treatment of the infection often dramatically improves apparent incontinence even before any sphincter-targeted medication is started. Our dog urinary tract infection guide covers the diagnosis and treatment of these common confounders.

Long-Term Use and Monitoring

Most dogs on Proin stay on the medication long-term because USMI does not typically resolve on its own. Once the right dose is established, many dogs do well for years on stable therapy. Regular rechecks every six to twelve months are appropriate for most dogs, with more frequent monitoring if any health concerns develop.

Bloodwork to monitor kidney function, blood pressure measurements, and a urinalysis to screen for UTI are reasonable parts of routine monitoring. Bring a current medication list to every visit, and report any changes in incontinence pattern, appetite, energy, or behavior.

Some dogs need dose adjustments over time as body weight changes, other health conditions develop, or sphincter tone changes with age. The goal is the lowest effective dose that controls the incontinence with minimal side effects.

When to Call Your Veterinarian

Call your vet promptly if your dog develops signs of significant hypertension (lethargy, weakness, vision changes, neurological signs), severe restlessness or agitation, decreased appetite that persists, vomiting, or any sudden behavioral change after starting or increasing Proin.

Also call if incontinence is not improving after two to three weeks of consistent dosing at the prescribed dose, or if it returns after a period of good control. Dose adjustments, addition of estrogen therapy, or further workup may be needed.

Never split or crush extended-release Proin tablets unless specifically directed by your vet. Doing so destroys the controlled-release mechanism and can cause significant side effects from rapid drug absorption.

Frequently Asked Questions

How fast does Proin work for incontinence?

Many dogs show meaningful improvement within a few days of starting therapy at an effective dose. Full assessment of response usually takes two to three weeks, during which dose adjustments may be made.

What is the difference between Proin chewable and Proin ER?

Chewable tablets are typically dosed two to three times daily, while ER (extended release) tablets are dosed once daily. ER tablets must be given whole and never crushed or split. The choice depends on convenience and tolerance.

Can my dog take Proin if she has a heart murmur?

It depends on the type and severity of the heart condition. Mild murmurs in otherwise healthy dogs may not preclude Proin use, but careful monitoring is appropriate. Significant cardiac disease often warrants alternative therapies. Discuss with your vet, ideally with cardiac evaluation as needed.

Why is blood pressure monitoring important?

PPA can elevate blood pressure through alpha-adrenergic effects. Hypertension in dogs often has no external signs, so monitoring is the only way to catch problems before they cause damage to the kidneys, eyes, or other organs.

What if I miss a dose of Proin?

Give the missed dose as soon as you remember if it has only been a few hours. If the next dose is approaching, skip the missed dose and resume the regular schedule. Never double up.

Can Proin be combined with estrogen therapy?

Yes, in some dogs the combination produces better incontinence control than either alone. Combination therapy requires veterinary guidance because of additional monitoring needs and potential drug interactions.